Goldman Sachs Group Inc Larimar Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,152,228 shares of LRMR stock, worth $13.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,152,228
Previous 4,249,491
2.29%
Holding current value
$13.8 Million
Previous $27.8 Million
43.02%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$70.7 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$21.5 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$20.1 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$15.5 Million7.6% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$11.4 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $144M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...